Page last updated: 2024-08-17

levodopa and coenzyme q10

levodopa has been researched along with coenzyme q10 in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (60.00)29.6817
2010's4 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Dirr, A; Gerlach, M; Gerstner, A; Götz, ME; Harth, R; Janetzky, B; Kuhn, W; Riederer, P1
Olanow, CW; Schapira, AH1
Fahn, S1
Jankovic, J; Olanow, CW1
Durner, J; Fuchs, G; Greulich, W; Henningsen, H; Herting, B; Jost, WH; Koch, R; Kuhn, W; Kupsch, A; Müller, T; Niklowitz, P; Oertel, WH; Reichmann, H; Spiegel, J; Storch, A; Vieregge, P1
Abdin, AA; Hamouda, HE1
Hauser, RA1
Belcastro, V; Caccamo, D; Calabresi, P; Currò, M; Ferlazzo, N; Gorgone, G; Ientile, R; Parisi, G; Parnetti, L; Pisani, F; Rossi, A; Tambasco, N1
Attia, HN; Maklad, YA1

Reviews

4 review(s) available for levodopa and coenzyme q10

ArticleYear
Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.
    JAMA, 2004, Jan-21, Volume: 291, Issue:3

    Topics: Antioxidants; Antiparkinson Agents; Clinical Trials as Topic; Coenzymes; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Ubiquinone

2004
ALS lessons learned from other neurological diseases. Parkinson's disease.
    Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, Volume: 5 Suppl 1

    Topics: Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Behavioral Symptoms; Coenzymes; Controlled Clinical Trials as Topic; Disease Progression; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Ubiquinone

2004
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20 Suppl 11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Coenzymes; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Indans; Levodopa; Membrane Proteins; N-Methylaspartate; Neuroprotective Agents; Parkinson Disease; Prostaglandin-Endoperoxide Synthases; Ubiquinone; Vitamin E

2005
Early pharmacologic treatment in Parkinson's disease.
    The American journal of managed care, 2010, Volume: 16 Suppl Implications

    Topics: Antiparkinson Agents; Disease Progression; Dopamine Agonists; Early Diagnosis; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Ubiquinone; Vitamin E

2010

Trials

1 trial(s) available for levodopa and coenzyme q10

ArticleYear
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
    Archives of neurology, 2007, Volume: 64, Issue:7

    Topics: Adult; Aged; Antioxidants; Cell Respiration; Coenzymes; Dopamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Energy Metabolism; Female; Humans; Levodopa; Male; Middle Aged; Neurons; Oxidative Stress; Parkinson Disease; Placebos; Substantia Nigra; Treatment Outcome; Ubiquinone; Vitamins

2007

Other Studies

5 other study(ies) available for levodopa and coenzyme q10

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Altered redox state of platelet coenzyme Q10 in Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2000, Volume: 107, Issue:1

    Topics: Aged; Aged, 80 and over; Antioxidants; Antiparkinson Agents; Biomarkers; Blood Platelets; Coenzymes; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Oxidation-Reduction; Parkinson Disease; Selegiline; Ubiquinone

2000
Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism.
    Neuropharmacology, 2008, Volume: 55, Issue:8

    Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Levodopa; Mitochondria; NAD; Neurons; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2; Psychomotor Performance; Rats; Rotenone; Spectrophotometry; Ubiquinone; Ultrasonography; Vitamins

2008
Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients.
    Neuromolecular medicine, 2012, Volume: 14, Issue:1

    Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; Ubiquinone; Vitamin B 12

2012
Neuroprotective effects of coenzyme Q10 on paraquat-induced Parkinson's disease in experimental animals.
    Behavioural pharmacology, 2018, Volume: 29, Issue:1

    Topics: Animals; Disease Models, Animal; Levodopa; Male; Mice; Mitochondria; Neurons; Neuroprotective Agents; Oxidative Stress; Paraquat; Parkinson Disease; Protein Carbonylation; Ubiquinone

2018